Clozapine


Atypical antipsychotic / D4-D2 multireceptor antagonist

The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.

Abstract

Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph